{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:14:00Z","timestamp":1791209640286,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1097\/01.ico.0000240079.24583.a1","type":"journal-article","created":{"date-parts":[[2006,12,22]],"date-time":"2006-12-22T04:10:46Z","timestamp":1166760646000},"page":"84-89","source":"Crossref","is-referenced-by-count":34,"title":["Comparison of Topical Dry Eye Medications for the Treatment of Keratoconjunctivitis Sicca in a Botulinum Toxin B-Induced Mouse Model"],"prefix":"10.1097","volume":"26","author":[{"given":"Kaevalin","family":"Lekhanont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya M","family":"Leyngold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olan","family":"Suwan-Apichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Rangsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S","family":"Chuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210204","first-page":"221","article-title":"Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes.","volume":"21","author":"Lemp","year":"1995","journal-title":"CLAO J"},{"key":"R2-15-20210204","first-page":"1356","article-title":"Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes.","volume":"41","author":"Brignole","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-15-20210204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1542-0124(12)70005-8","article-title":"Anti-inflammatory therapy of dry eye.","volume":"1","author":"Pflugfelder","year":"2003","journal-title":"The Ocular Surface"},{"key":"R4-15-20210204","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","article-title":"Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogrens syndrome.","volume":"106","author":"Marsh","year":"1999","journal-title":"Ophthalmology"},{"key":"R5-15-20210204","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","article-title":"Topical cyclosporine treatment of keratoconjunctivitis sicca in secondary Sjogrens syndrome.","volume":"72","author":"Gunduz","year":"1994","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R6-15-20210204","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease CsA Phase 3 Study Group.","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"R7-15-20210204","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine.","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"R8-15-20210204","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1006879618176","article-title":"Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia\/reperfusion injury.","volume":"174","author":"Halestrap","year":"1997","journal-title":"Mol Cell Biochem"},{"key":"R9-15-20210204","first-page":"90","article-title":"Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporine A.","volume":"42","author":"Brignole","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-15-20210204","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.120.3.330","article-title":"Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine.","volume":"120","author":"Kunert","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R11-15-20210204","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ophtha.2003.07.008","article-title":"Sequential changes of lipid tear film after the instillation of a single drop of a new emulsion eye drop in dry eye patients.","volume":"11","author":"Di Pascuale","year":"2004","journal-title":"Ophthalmology"},{"key":"R12-15-20210204","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/S0161-6420(02)01262-9","article-title":"Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction.","volume":"109","author":"Goto","year":"2002","journal-title":"Ophthalmology"},{"key":"R13-15-20210204","first-page":"632","article-title":"A mouse model of keratoconjunctivitis sicca.","volume":"43","author":"Dursun","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-15-20210204","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/jop.1995.11.503","article-title":"Establishment of a rabbit short-term dry eye model.","volume":"11","author":"Fujihara","year":"1995","journal-title":"J Ocul Pharmacol Ther"},{"key":"R15-15-20210204","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/archopht.118.2.246","article-title":"Tear production after unilateral removal of the main lacrimal gland in squirrel monkeys.","volume":"118","author":"Maitchouk","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R16-15-20210204","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1167\/iovs.04-1344","article-title":"D-beta-hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board.","volume":"46","author":"Nakamura","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-15-20210204","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum toxin: mechanisms of action.","volume":"53","author":"Dressler","year":"2005","journal-title":"Eur Neurol"},{"key":"R18-15-20210204","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0161-6420(88)32977-5","article-title":"Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.","volume":"95","author":"Dutton","year":"1988","journal-title":"Ophthalmology"},{"key":"R19-15-20210204","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/bjo.87.1.54","article-title":"Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.","volume":"87","author":"Horwath-Winter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R20-15-20210204","first-page":"149","article-title":"Decreased tear expression with an abnormal Schirmers test following botulinum toxin type A for the treatment of lateral canthal rhytides.","volume":"28","author":"Matarasso","year":"2002","journal-title":"Dermatol Surg"},{"key":"R21-15-20210204","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.joms.2003.09.015","article-title":"The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes.","volume":"62","author":"Kyrmizakis","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"R22-15-20210204","first-page":"7","article-title":"Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides.","volume":"29","author":"Matarasso","year":"2003","journal-title":"Dermatol Surg"},{"key":"R23-15-20210204","first-page":"519","article-title":"Botulinum toxin B (Myobloc) versus botulinum toxin A (Botox) frontalis study: rate of onset and radius of diffusion.","volume":"29","author":"Flynn","year":"2003","journal-title":"Dermatol Surg"},{"key":"R24-15-20210204","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1167\/iovs.05-0380","article-title":"Botulinum toxin B induced mouse model of keratoconjunctivitis sicca.","volume":"47","author":"Suwan-Apichon","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-15-20210204","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.eye.6700230","article-title":"Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland.","volume":"16","author":"Montoya","year":"2002","journal-title":"Eye"},{"issue":"Suppl 2","key":"R26-15-20210204","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S0039-6257(00)00200-9","article-title":"The pathology of dry eye.","volume":"45","author":"Baudouin","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"R27-15-20210204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1567-424X(09)70353-8","article-title":"Botulinum toxin mechanisms of action.","volume":"57","author":"Dressler","year":"2004","journal-title":"Suppl Clin Neurophysiol"},{"key":"R29-15-20210204","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/jop.2005.21.139","article-title":"Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye.","volume":"21","author":"Nagelhout","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"R30-15-20210204","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0002-9394(03)00326-X","article-title":"The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study.","volume":"136","author":"Avunduk","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R31-15-20210204","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R32-15-20210204","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Cyclosporine A phase 2 study group. Efficacy and safety of cyclosporine: a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease a dose-ranging, randomized trial.","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"R33-15-20210204","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes.","volume":"118","author":"Kunert","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R34-15-20210204","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00003226-200007000-00018","article-title":"Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion.","volume":"19","author":"Turner","year":"2000","journal-title":"Cornea"},{"key":"R35-15-20210204","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1167\/iovs.04-0299","article-title":"Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells.","volume":"45","author":"Li","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R36-15-20210204","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0002-9440(10)62232-8","article-title":"Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye.","volume":"166","author":"Pflugfelder","year":"2005","journal-title":"Am J Pathol"},{"key":"R37-15-20210204","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0002-9394(01)00913-8","article-title":"Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids.","volume":"132","author":"Dursun","year":"2001","journal-title":"Am J Ophthalmol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-200701000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:18:48Z","timestamp":1786033128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-200701000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ico.0000240079.24583.a1","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}